Delivery Order SPE2DB20D2001-SPE2DB22FM28B
- Not listed
- This federal contract award, valued at $3,020.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a delivery order, is for the supply of Restasis 0.05% eye emulsion. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC...
- This federal contract award, valued at $5,579.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Restasis 0.05% eye emulsion, a specialty pharmaceutical product. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Restasis 0.05% Eye Emulsion 30s. The $2,853.54 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to provide a comprehensive range of...
- This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, involves the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA) Troop Support Medical. The $1,080.48 firm fixed-price delivery order is placed against an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA. This IDC serves as a primary vehicle for the company to provide a comprehensive range of pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,938.39 contract is for the delivery of Restasis 0.05% eye emulsion. The contract has a completion date of June 29, 2022 and is a firm fixed-price delivery order. This award is associated with AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Restasis 0.05% eye emulsion. The $16,124.33 firm fixed-price delivery order is a component of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
- This federal contract award is a delivery order valued at $2,352.00 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,800.80 for the supply of Restasis 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle for the company to provide a comprehensive range...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Restasis 0.05% eye emulsion. The contract, valued at $3,180.58, is a firm fixed-price delivery order with a completion date of November 26, 2021. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 3, 2022. The contract, valued at $9,109.98, is for the delivery of RESTASIS 0.05% eye emulsion. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999 and running through November 2026. The IDC serves as a primary...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB22FM28BDelivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,834.03, is for the delivery of Restasis 0.05% eye emulsion, a prescription eye medication. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions globally. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs. These IDCs demonstrate AmerisourceBergen's capacity to efficiently supply critical pharmaceutical and medical commodities to various government agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.8k | 10/27/21 |